pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 9·1 min read
save

FDA approves first new sunscreen ingredient in over 25 years

Jun 9, 2026·read at STAT ↗RegulatoryPositive

The U.S. Food and Drug Administration has cleared a new sunscreen active called bemotrizinol, the first novel ingredient to receive approval in more than a quarter‑century.

The agency said the chemical meets its safety criteria, causing little irritation and minimal absorption into the skin, and it is deemed safe for adults and children six months of age and older.

Dutch firm DSM Nutritional Products will initially market the ingredient under the brand name Parsol Shield, with an 18‑month exclusivity period before other manufacturers can use it. The product is expected to launch later this year, offering a new option for UV protection in the U.S. market.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “FDA OKs first new sunscreen ingredient in more than 25 years”

read at STAT ↗
591 words · retrieved Jun 9
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECAGILEAD
drugs
ObesityZINC
topics
Dermatology5Approval2MelanomaObesityOncologyType 2 Diabetes

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • 6d agoSTAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT
  • Jun 9Gilead and Merck’s latest trial success and flopSTAT
  • Aug 20Chutes & Ladders—Neumora shuffles leadership ahead of INDFierce Biotech
  • Aug 13Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionFierce Biotech